Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.23750/abm.v91i4.10681 http://scihub22266oqcxt.onion/10.23750/abm.v91i4.10681 33525227!7927533!33525227     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Acta+Biomed 2020 ; 91 (4): e2020175 Nephropedia Template TP {{tp|p=33525227|t=2020. Current Perspectives of convalescent plasma therapy in COVID-19 |pdf=|usr=}}{{33525227}} gab.com Text Current Perspectives of convalescent plasma therapy in COVID-19 JO: Acta Biomed http://www.kidney.de/pget.php?&tw=1&pmid=33525227 #FOAvip The outbreak of the coronavirus disease 2019 (COVID-19) has posed an unprecedented challenge to the health care communities across the globe. As of June 2, 2020, a total of 6,418,968 confirmed COVID-19 cases with 378,954 deaths have been reported. Different regions of the world have reported varying intensity of COVID-19 severity. The disease burden for COVID-19 depends on multiple factors like the local infection rate, susceptible population, mortality rate, and so on. The COVID-19 pandemic is a rapidly evolving emergency and is a subject of regular debate and advanced research. As of today, there is a lack of definitive treatment options for COVID-19 pneumonia. In search of alternative options, few drugs are being tested for their efficacy and repurposing. Preliminary reports have shown positive outcomes with Remdesivir and tocilizumab, but this needs further confirmation. Recently, the therapeutic application of Convalescent Plasma therapy in critically ill patients suffering from COVID-19 has gained momentum. We hereby discuss the convalescent plasma as a potential therapeutic option, its challenges of finding the ideal donors, transfusion medicine responsibilities, and the current global experience with its use. Twit Text FOAVip Current Perspectives of convalescent plasma therapy in COVID-19 ????Acta Biomed http://www.kidney.de/pget.php?&tw=1&pmid=33525227 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33525227 #FOAvip English Wikipedia <ref>{{Cite pmid|33525227}}</ref> Current Perspectives of convalescent plasma therapy in COVID-19 #MMPMID33525227 Sahu KK; Mishra AK; Raturi M; Lal A Acta Biomed 2020[Nov]; 91 (4): e2020175 PMID33525227show ga The outbreak of the coronavirus disease 2019 (COVID-19) has posed an unprecedented challenge to the health care communities across the globe. As of June 2, 2020, a total of 6,418,968 confirmed COVID-19 cases with 378,954 deaths have been reported. Different regions of the world have reported varying intensity of COVID-19 severity. The disease burden for COVID-19 depends on multiple factors like the local infection rate, susceptible population, mortality rate, and so on. The COVID-19 pandemic is a rapidly evolving emergency and is a subject of regular debate and advanced research. As of today, there is a lack of definitive treatment options for COVID-19 pneumonia. In search of alternative options, few drugs are being tested for their efficacy and repurposing. Preliminary reports have shown positive outcomes with Remdesivir and tocilizumab, but this needs further confirmation. Recently, the therapeutic application of Convalescent Plasma therapy in critically ill patients suffering from COVID-19 has gained momentum. We hereby discuss the convalescent plasma as a potential therapeutic option, its challenges of finding the ideal donors, transfusion medicine responsibilities, and the current global experience with its use. |COVID-19 Serotherapy[MESH] |COVID-19/*therapy[MESH] |Humans[MESH] |Immunization, Passive[MESH]Current Perspectives of convalescent plasma therapy in COVID-19 (epmc).pdf DeepDyve Pubget Overpricing